An international multicenter efficacy and safety study of IqYmune in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study-Reference-Cited by-同舟云学术

An international multicenter efficacy and safety study of IqYmune in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study

Published:2020-08-31 Issue:4 Volume:25 Page:356-365
ISSN:1085-9489
Container-title:Journal of the Peripheral Nervous System
language:en
Short-container-title:J Peripher Nerv Syst

Author:

Nobile‐Orazio Eduardo¹^ORCID,Pujol Sonia²^ORCID,Kasiborski Fabrice²,Ouaja Rabye²^ORCID,Corte Gilles Della³,Bonek Robert⁴,Cocito Dario⁵^ORCID,Schenone Angelo⁶

Affiliation:

1. Neuromuscular and Neuroimmunology Service, IRCCS Humanitas Clinical and Research Center Milan University Via Manzoni 56, Rozzano Milan 20089 Italy

2. LFB Les Ulis France

3. Dellmed Consulting Ornex France

4. Department of Neurology NeuroCenter, Regional Specialist Hospital Bydgoszcz Poland

5. Istituti Clinici Scientifici Maugeri Turin Italy

6. Department of Neurosciences, Rehabilitation, Ophthalmology, Genetic and Maternal and Infantile Sciences (DINOGMI) University of Genova and IRCCS Policlinico San Martino Genova Italy

Publisher

Wiley

Subject

Neurology (clinical),General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jns.12408

Reference18 articles.

1. Advances in the diagnosis, pathogenesis and treatment of CIDP

2. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England

3. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial

4. Efficacy and safety of Privigen ® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single‐arm, open‐label Phase III study (the PRIMA study)

5. A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment response amplitude and timing in chronic inflammatory demyelinating polyneuropathy with routine care: Study of a UK cohort;European Journal of Neurology;2024-07-09

2. Prospective open-label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies;Journal of Neurology, Neurosurgery & Psychiatry;2024-05-10

3. Current clinical management of CIDP with immunoglobulins in France: An expert opinion;Revue Neurologique;2023-10

4. Time for a standardized diagnostic response test in patients with chronic inflammatory demyelinating polyradiculoneuropathy?;Brain and Behavior;2023-09-24

5. Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study;Drug Safety;2023-06-28